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Signaling at NMDA receptors (NMDARs) is known to be important for memory reconsolidation, but while most studies show that
NMDAR antagonists prevent memory restabilization and produce amnesia, others have shown that GluN2B-selective NMDAR antago-
nists prevent memory destabilization, protecting the memory. These apparently paradoxical, conflicting data provide an opportunity to
define more precisely the requirement for different NMDAR subtypes in the mechanisms underlying memory reconsolidation and to
further understand the contribution of glutamatergic signaling to this process. Here, using rats with fully consolidated pavlovian audi-
tory fear memories, we demonstrate a double dissociation in the requirement for GluN2B-containing and GluN2A-containing NMDARs
within the basolateral amygdala in the memory destabilization and restabilization processes, respectively. We further show a double
dissociation in the mechanisms underlying memory retrieval and memory destabilization, since AMPAR antagonism prevented memory
retrieval while still allowing the destabilization process to occur. These data demonstrate that glutamatergic signaling mechanisms
within the basolateral amygdala differentially and dissociably mediate the retrieval, destabilization, and restabilization of previously
consolidated fear memories.
Introduction
Memory reconsolidation is the process by which previously con-
solidated memories become destabilized at retrieval and require
restabilization to persist in the brain (Lewis, 1979; Nader, 2003).
The neurochemical basis of reconsolidation has been intensively
studied, particularly the requirement for signaling at the NMDA
subtype of glutamate receptor (NMDAR). However, although
NMDAR-mediated signaling is required for the reconsolidation
(restabilization) of conditioned stimulus (CS)– drug (Sadler et
al., 2007; Brown et al., 2008; Itzhak, 2008; Milton et al., 2008;
Milton et al., 2012), CS–spatial (Przybyslawski and Sara, 1997),
and CS–fear (Pedreira et al., 2002; Lee et al., 2006) memories,
antagonism at the GluN2B subtype of NMDAR has been shown
to prevent the destabilization of CS–fear memories, thereby pro-
tecting them from the effects of amnestic agents (Ben Mamou et
al., 2006). These paradoxical, apparently conflicting data provide
the opportunity to better understand the contribution of signal-
ing at glutamatergic receptors to the reconsolidation process.
NMDARs exist as tetramers, typically composed of two GluN1
and two GluN2 subunits (Dingledine et al., 1999). The GluN2 sub-
units consist of four different types (GluN2A–D), of which GluN2A
and GluN2B have been the most studied. In addition to differences
between GluN2A-containing (GluN2A-NMDARs) and GluN2B-
containing NMDARs (GluN2B-NMDARs) in their sensitivity to
glutamate and their activation kinetics, these subtypes of receptor
also couple to different proteins within the postsynaptic density,
activating divergent intracellular signaling pathways (Kim et al.,
2005; Ivanov et al., 2006; Zhang et al., 2008). For example, the
C-terminal domain of GluN2B-NMDARs suppresses CREB and ac-
tivates the ubiquitin–proteasome system (UPS), while GluN2A-
NMDAR activation promotes CREB phosphorylation and is
neuroprotective (Hardingham et al., 2002; Martel et al., 2012). These
differences at the molecular level may have important functional
implications; activation of GluN2B-NMDARs promotes long-term
depression (LTD), while activation of GluN2A-NMDARs promotes
long-term potentiation (LTP) in the hippocampus (Liu et al., 2004).
The basolateral amygdala (BLA) is required for both CS–fear
memory consolidation (Campeau and Davis, 1995; Killcross et
al., 1997; Koo et al., 2004) and reconsolidation (Nader et al.,
2000). Furthermore, NMDARs within the BLA have been impli-
cated in both memory destabilization (Ben Mamou et al., 2006)
and restabilization (Milton et al., 2008) processes. Thus, we hy-
pothesized that memory destabilization and restabilization may
be mediated through the different subtypes of NMDAR within
the BLA, GluN2B-NMDARs being required for destabilization
and GluN2A-NMDARs being required for restabilization. Fur-
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thermore, since AMPARs are required for memory retrieval (Day
et al., 2003; Bast et al., 2005; Winters and Bussey, 2005) and
because memory reconsolidation can only occur when a memory
is retrieved (Lewis, 1979; Nader, 2003), we further hypothesized
that AMPARs would be necessary for the destabilization process.
Finally, we investigated the effects of reducing presynaptic gluta-
mate release by treatment with an agonist at metabotropic 2/3
glutamate receptors (mGlu2/3Rs) on the balance of these mne-
monic processes. We hypothesized that the memory should nei-
ther be retrieved nor destabilized, and therefore restabilization of
the memory would not be required for it to persist.
Materials and Methods
Subjects. Subjects were 93 male Lister–Hooded rats (Charles River Labo-
ratories) housed in pairs in a vivarium on a reversed light-dark cycle
(lights on at 1900 h). Subjects were food restricted, although not de-
prived, being fed 25 g per rat of lab chow after training or testing each day.
Access to water was ad libitum except for when inside the conditioning
chambers. All procedures were conducted in accordance with the UK
Animals (Scientific Procedures) Act 1986.
Surgery. Rats were implanted with bilateral guide cannulae (16 mm, 24
gauge; Coopers Needle Works) located just dorsal to the basolateral
amygdala (Fig. 1) as described previously (Milton et al., 2008). The co-
ordinates for cannula implantation were anteroposterior  2.6 mm and
mediolateral  4.5 mm (relative to bregma) and dorsoventral  5.6 mm
(relative to dura). A recovery period of 7 days was given before behavioral
training and testing began.
Intracerebral drug administration. Infusions were carried out using a
syringe pump (Harvard Apparatus) and 5 l Hamilton syringes con-
nected to injectors (28 gauge, projecting 2 mm beyond the guide cannu-
lae; Plastics One) by polyethylene tubing. The rats received two infusions:
one immediately before the memory reactivation session, and one im-
mediately afterward. All infusions were begun 30 s after the insertion of
the injectors and performed over 2 min at a rate of 0.25 l min 1 (total
volume of 0.5 l side 1). One minute of waiting time was imposed from
the end of the infusion to the removal of the injectors to allow diffusion
of the solution away from the infusion site.
Drugs. Rats received either the protein synthesis inhibitor anisomycin
or its vehicle as their second (post-reactivation) infusion. Anisomycin
(125 g l 1; Sigma-Aldrich) was dissolved in equimolar HCl and then
pH balanced to pH 7.4 with NaOH. This dose of anisomycin has previ-
ously been shown to disrupt memory reconsolidation (Ben Mamou et al.,
2006).
Prior to memory reactivation, rats received infusions of drugs target-
ing the glutamatergic signaling system or the appropriate vehicle. The
GluN2B diheteromeric receptor-selective (Williams, 1993) NMDAR an-
tagonist ifenprodil (Ascent Scientific) was dissolved in PBS at a concen-
tration of 2 g l 1; this dose has previously been shown to disrupt
memory destabilization (Ben Mamou et al., 2006). The GluN2A-
preferring (Auberson et al., 2002) NMDAR antagonist NVP-AAM077
(Sigma-Aldrich) was dissolved in PBS at a concentration of 5 g l 1;
this dose has been shown to reduce the expression of fear-potentiated
startle (Walker and Davis, 2008). The mGlu2/3R agonist LY317206 (Do-
herty et al., 1999) and the AMPAR antagonist LY293558 (Ornstein et al.,
1993) were both generous gifts from Eli Lilly. LY317206 was dissolved in
PBS at a concentration of 2 g l 1, and LY293558 in ddH2O at a
concentration of 1.33 g l 1. This dose of LY317206 has been shown to
reduce fear-potentiated startle (Walker et al., 2002), and the dose of
LY293558 is higher than the ineffective doses used previously in the
amygdala (Di Ciano and Everitt, 2004).
Behavioral procedures. Testing took place in four conditioning cham-
bers (Med Associates) with the assignment of individual conditioning
chambers counterbalanced across experimental groups within each ex-
periment. Rats were first habituated to the context in a 2 h session in
which neither the clicker CS nor the shock unconditioned stimulus (US)
were presented. Following the end of this habituation session, they were
returned to the home cage. Twenty-four hours later, they were placed
back into the same experimental chamber for the fear conditioning ses-
sion; during this time, they were first exposed to the context (with no CS
or US) for 35  1 min, then exposed to a single CS–US pairing of a clicker
(10 Hz, 80 dB, 60 s) CS and a 0.5 mA, 1 s scrambled footshock US. For the
experiment investigating the requirement of AMPARs in memory recon-
solidation, a different brand of experimental chamber (Paul Fray Lim-
ited) was used, but it was set up in the same configuration as the Med
Associates chambers, other than the shock duration (0.5 s). To ensure
comparability in the strength of learning, five CS-shock pairings were
used in this experiment. All other aspects of the behavioral procedures
remained the same.
Twenty-four hours following the end of training, the rats were re-
turned to the same conditioning chambers for a memory reactivation
session. After 1 min of context exposure, the clicker CS was presented for
60 s. The session was recorded through a CCTV system onto a DVD to
allow for offline manual scoring of behavior. Two CS–fear memory tests
were conducted following the memory reactivation session; these test
sessions, conducted 24 h and 8 d following reactivation, had the same
format as the memory reactivation session, except that no drug infusions
were given.
Briefly, and as before (Ben Mamou et al., 2006), if memory destabili-
zation was prevented by the pre-reactivation infusion, then anisomycin
would not have an amnestic effect when it was subsequently infused,
since the memory would not be in a destabilized and labile state when
anisomycin was applied. If memory restabilization was prevented by the
pre-reactivation infusion, then all experimental groups treated with the
drug would be predicted to show amnesia at subsequent test, as would a
group that had received an infusion of vehicle followed by anisomycin. If
neither destabilization nor restabilization were prevented by the pre-
reactivation infusion, then only the two groups that had received post-
reactivation anisomycin would be predicted to show amnesia.
Histology. At the end of the experiments, the rats were killed with an
overdose of anesthetic (Dolethal, Vétoquinol) and transcardially per-
fused through the ascending aorta with 0.01 M PBS, followed by 4%
paraformaldehyde (PFA). The brains were removed and stored in 4%
PFA for at least 24 h before being transferred to a 20% sucrose solution
for cryoprotection before sectioning. The brains were sectioned at 60 m
and stained with cresyl violet. Cannulae placements (Fig. 1) were verified
using light microscopy (Leica).
Data collection and statistical analysis. Data for the reactivation and test
sessions were scored offline and blind to treatment by A.L.M. Data from
the conditioning session were not recorded because there is no measure
of conditioned freezing when animals receive only one pairing of the CS
with shock. However, shock delivery was recorded by the experimenter
observing the unconditioned response in the conditioning session.
Freezing was defined as a cessation of movement apart from respiration
and was measured instantaneously at 5 s intervals. Freezing during the
first minute of the session was assessed to provide a measure of fear to the
context, and the second as a measure of fear to the CS. All data were
converted to percentages before analysis. Data were analyzed by
repeated-measures ANOVA with CS (context vs cue) and Session (reac-
tivation vs 24 h test vs 8 d test) as within-subject factors, and Drug 1
[vehicle (VEH) vs drug] and Drug 2 [VEH vs anisomycin (ANI)] as
between-subjects factors. For clarity, these are reported in the text using
the name of the drug used in the experimental group (e.g., Drug 2 is
shown as ANI). Where the data violated the assumption of sphericity as
assessed using Mauchly’s test, a correction was applied; the Greenhouse–
Geisser correction if   0.75, and the Huynh–Feldt correction if  
0.75, as recommended by Cardinal and Aitken (2006). Where appro-
priate, further ANOVAs or pairwise comparisons were conducted; all
pairwise comparisons were adjusted using the Šidák correction,
which is a mathematically accurate form of the Bonferroni estimation
(Cardinal and Aitken, 2006).
Results
GluN2B-NMDARs are required for memory destabilization,
not restabilization
Administration of the GluN2B-selective NMDAR antagonist if-
enprodil (IFEN) directly into the BLA before memory reactiva-
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tion prevented the destabilization of the CS–fear memory. This
was shown by the prevention of anisomycin-induced amnesia
when IFEN was given before reactivation, but not when the ve-
hicle was given before reactivation (Fig. 2b). All groups had pre-
viously conditioned to the CS, as all rats showed greater freezing
to the CS than the context in the reactivation and the test sessions
[F1, 25  33.0, p  0.001, 
2  0.57]. While the VEH/ANI group
showed less freezing than the VEH/VEH group at the 24 h test
[F
(1, 14)
 5.8, p  0.031,  2  0.29], the IFEN/ANI group froze
comparably to the IFEN/VEH group [F  1, p  0.66]. Analysis
of the 8 d test was complicated by an overall reduction in condi-
tioned freezing [CS  session: F1, 25  4.7, p  0.04, 
2  0.16]
most likely attributable to the gradual extinction that occurred
after the last nonreinforced retrieval test. However, while the
Figure 1. Cannulae placements. All cannulae placements were within the BLA. The placements for individual experiments are shown separately. For each placement the white circles represent
the vehicle/vehicle group, the white squares the vehicle/anisomycin group, the gray circles the drug/vehicle group, and the gray squares the drug/anisomycin group where the drugs were IFEN (a),
NVP-AAM077 (b), LY293558 (c), and LY317206 (d). Coordinates are given from bregma. This figure was modified, with permission, from Paxinos and Watson (2004).
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VEH/VEH and VEH/ANI groups showed equivalent conditioned
freezing at the 8 d test [F1, 14  2.2, p  0.16], so did the IFEN/
VEH and IFEN/ANI groups [F1, 11  3.4, p  0.09], consistent
with the prevention of destabilization of the CS–fear memory by
IFEN.
IFEN did not acutely affect the retrieval of the conditioned
fear memory (Fig. 2a); collapsing across groups for the first infu-
sion (VEH, n  16; IFEN, n  13) there was no difference in the
level of conditioned freezing shown during the memory reactiva-
tion session [F  1, p  0.95]. These findings confirm the previ-
ous report (Ben Mamou et al., 2006) that GluN2B-NMDARs are
required for memory destabilization.
GluN2A-NMDARs are required for memory restabilization,
not destabilization
Administration of the GluN2A-preferring NMDAR antagonist
NVP-AAM077 (NVP) before the memory reactivation session
reduced conditioned freezing at subsequent tests conducted 24 h
and 8 d later (Fig. 3b). All rats had conditioned to the CS, as all
groups showed greater freezing to the CS than the context in the
reactivation and the test sessions [F1, 15  12, p  0.003, 
2 
0.45]. Administration of NVP reduced conditioned freezing in
the subsequent test sessions [CS  Session  NVP: F2, 30  4.8,
p  0.016,  2  0.24], but not during the reactivation session.
Analyses of individual sessions showed that there were no differ-
ences between experimental groups during reactivation [CS 
NVP: F1, 15  2.3, p  0.15; CS  ANI: F  1, p  0.52; CS 
NVP  ANI: F  1, p  0.87], but NVP-treated animals froze less
than VEH-treated rats during the test at 24 h [CS  NVP: F1, 15 
8.5, p  0.011,  2  0.36]. The effect of NVP was persistent in
that there was no overall reduction in freezing between the 24 h
and the 8 d test [F 1], although there was a reduction in the
VEH-treated groups [CS  Session  NVP: F1, 15  9.75, p 
0.007,  2  0.39; pairwise comparisons showed a reduction in
conditioned freezing between the 24 h and 8 d test in the VEH-
treated groups, p  0.024, but not in the NVP-treated groups, p 
0.22]. This is consistent with extinction of the CS–US association
in the VEH/VEH group, but not in the other experimental
groups, which could not reduce freezing any further. Pairwise
comparisons also revealed that the NVP-treated groups did not
differ from the VEH/ANI group [all p values  0.41]. Thus, ad-
ministration of NVP produced amnesia regardless of whether
anisomycin was also administered. Furthermore, the amnesia
shown by the NVP/ANI group supports the view that NVP did
not block destabilization, because if it had then this group would
have shown intact memory.
NVP did not acutely affect the retrieval of the conditioned fear
memory during the reactivation session (Fig. 3a); collapsing
across groups for the first infusion (VEH, n  9; NVP, n  10),
despite the apparent numerical reduction in freezing in the NVP-
treated group, there was no statistical difference between freezing
levels in the two experimental groups [F1, 17  2.4, p  0.14].
However, the NVP-treated group showed levels of freezing that
did not significantly differ from zero [p  0.34] consistent with
the previous observation that this dose of NVP reduces the ex-
pression of fear-potentiated startle (Walker and Davis, 2008).
This result supports our hypothesis that GluN2A-NMDARs are
required for memory restabilization while not being required for
memory destabilization.
AMPARs are not required for destabilization
or restabilization
Administration of the AMPAR antagonist LY293558 before
memory reactivation did not reduce conditioned freezing during
the test sessions and did not prevent the post-reactivation aniso-
mycin infusion from inducing amnesia (Fig. 4b). All rats had
conditioned to the CS, as they showed greater freezing to the CS
than the context following training [F1, 21  37.7, p  0.001, 
2 
Figure 2. Effects of the GluN2B-selective NMDAR antagonist on CS–fear memory reconsoli-
dation. Administration of the GluN2B-selective NMDAR antagonist had no effect on the retrieval
of the CS–fear memory at reactivation (a), but it did prevent the destabilization of the CS–fear
memory (b). Data are presented as means  SEM. Group sizes (and colors in b) were VEH/VEH,
n  8 (white); IFEN/VEH, n  8 (mid-gray); VEH/ANI, n  8 (pale gray); and IFEN/ANI, n  5
(dark gray). In a the groups are collapsed with the white bar representing the average of the
VEH/VEH and VEH/ANI groups, and the gray bar the IFEN/VEH and IFEN/ANI groups. Asterisk (*)
denotes p  0.05.
Figure 3. Effects of the GluN2A-preferring NMDAR antagonist on CS–fear memory recon-
solidation. Administration of the GluN2A-preferring NMDAR antagonist had no effect on the
retrieval of the CS–fear memory at reactivation (a), but it prevented the restabilization of the
CS–fear memory (b). Data are presented as means  SEM. Group sizes (and colors in b) were:
VEH/VEH, n4 (white); NVP/VEH, n5 (mid gray); VEH/ANI, n5 (pale gray); and NVP/ANI,
n  5 (dark gray). In a the groups are collapsed, with the white bar representing the average of
the VEH/VEH and VEH/ANI groups, and the gray bar the NVP/VEH and NVP/ANI groups. Asterisk
(*) denotes p  0.05; ns denotes nonsignificant differences.
Figure 4. Effects of the AMPAR antagonist on CS–fear memory reconsolidation. The AMPAR
antagonist LY293558 acutely impaired the retrieval of the CS–fear memory at reactivation (a),
but it affected neither the destabilization nor the restabilization of the CS–fear memory (b).
Group sizes (and colors in b) were VEH/VEH, n  8 (white); LY293558/VEH, n  6 (mid gray);
VEH/ANI, n  6 (pale gray); and LY293558/ANI, n  5 (dark gray). In a the groups are col-
lapsed, with the white bar representing the average of the VEH/VEH and VEH/ANI groups and
the gray bar the LY293558/VEH and LY293558/ANI groups. Asterisks (*) denote p  0.05.
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0.64]. LY293558 did not affect freezing in the 24 h test session
[CS  LY293558: F  1, p  0.45], but anisomycin infusion
resulted in amnesia [CS  ANI: F1, 21  16, p  0.001, 
2  0.44].
Indeed, the group that received anisomycin following LY293558
froze less than the group that received vehicle before reactivation
[CS  ANI: F1, 9  6.0, p  0.037, 
2  0.40], demonstrating that
LY293558 did not prevent the destabilization of the memory.
This anisomycin-induced amnesia was also observed at the 8 d
test [F1, 21  7.82, p  0.011, 
2  0.27], even though there was
extinction of conditioned freezing at the 8 d test compared to the
24 h test [F1, 21  10.1, p  0.005, 
2  0.32]. This is consistent
with a previous report in which the AMPA/kainate receptor an-
tagonist CNQX was shown to leave memory destabilization and
restabilization intact when given before memory reactivation
(Ben Mamou et al., 2006).
LY293558 acutely reduced conditioned freezing during the
memory-reactivation session (Fig. 4a); collapsing across groups
for the first infusion (VEH, n  14; LY293558, n  11), the
groups given LY293558 before the memory reactivation froze to
the CS less than groups that had received the infusion of vehicle
[CS  LY293558: F1, 23  6.8, p  0.016, 
2  0.23]. Thus,
AMPARs are required for memory retrieval but not memory
destabilization.
Blockade of Glu release left destabilization and
restabilization intact
LY317206, an agonist at presynaptic class II/III metabotropic glu-
tamate receptors (mGlu2/3Rs), affected neither the destabiliza-
tion nor the restabilization of the CS–fear memory (Fig. 5b). All
groups had conditioned to the CS during training, as shown by
increased freezing during the CS compared to the context [F1, 16
 29, p  0.001,  2  0.64]. However, although anisomycin
produced amnesia as assessed at the 24 h test [CS  ANI: F1, 16 
7.2, p  0.016,  2  0.31], there was no effect of LY317206 on
conditioned freezing [CS  LY317206: F  1, p  0.74], indicat-
ing that it did not prevent the restabilization of the CS–fear mem-
ory. Furthermore, as the LY317206/ANI group showed less
freezing to the CS than the LY317206/
VEH group at the 24 h test [CS  ANI: F1,
10  11, p  0.008,  2  0.52], the mem-
ory destabilized during the reactivation ses-
sion, and this process was not prevented by
agonism at mGlu2/3Rs. The anisomycin-
induced amnesia observed at 24 h persisted
at the trend level in the 8 d test [F1, 16  4.14,
p  0.059, 2  0.21], although the data
from the 8 d test were compromised by the
extinction of conditioned freezing in the
VEH/VEH group [pairwise comparisons
revealed reduced conditioned freezing at
the 8d test in this group, p  0.035, but
no differences in the other groups, all p
values  0.49].
LY317206 did not acutely affect the re-
trieval of the conditioned fear memory
during the reactivation session (Fig. 5a);
collapsing across groups for the first infu-
sion (VEH, n  8; LY317206, n  12),
there was no statistically significant differ-
ence between freezing levels in the two
groups [F1, 18  2.4, p  0.14] despite the
numerical reduction in conditioned
freezing. Thus, agonism at presynaptic
mGlu2/3Rs did not affect the destabilization or restabilization
and did not produce a statistically significant reduction in the
retrieval of the CS–fear memory.
Discussion
The present data support the view that GluN2B-NMDARs and
GluN2A-NMDARs within the BLA are required for memory de-
stabilization and restabilization, respectively. This is the first
demonstration of a double dissociation in the function of these
two subtypes of NMDAR in memory reconsolidation. Further-
more, we also demonstrate a double dissociation between mem-
ory retrieval (dependent upon AMPARs) and the induction of
memory lability (dependent upon GluN2B-NMDARs).
The doubly dissociable involvement of different NMDAR
subtypes in destabilization and restabilization enables resolution
of the apparent discrepant findings in the literature that antago-
nism at GluN2B-NMDARs prevents memory destabilization
(Ben Mamou et al., 2006), but that nonselective NMDAR antag-
onism with D-APV (Milton et al., 2008) or MK-801 (Przybyslawski
Figure 5. Effects of the mGlu2/3R agonist on CS–fear memory reconsolidation. The
mGlu2/3R agonist LY317206 did not prevent retrieval of the CS–fear memory at reactivation
(a), and it prevented neither destabilization nor restabilization of the CS–fear memory (b).
Group sizes (and colors in b) were VEH/VEH, n  4 (white); LY317206/VEH, n  6 (mid gray);
VEH/ANI, n  4 (pale gray); and LY317206/ANI, n  6 (dark gray). In a the groups are col-
lapsed, with the white bar representing the average of the VEH/VEH and VEH/ANI groups and
the gray bar the LY317206/VEH and LY317206/ANI groups. Asterisk (*) denotes p  0.05; ns
denotes nonsignificant differences.
Figure 6. Hypothesized glutamatergic mechanisms underlying memory stability. GluN2B-containing NMDARs are required for
memory destabilization, and IFEN prevents this process. GluN2A-containing NMDARs are required for memory restabilization,
which is prevented by NVP-AAM077. The AMPAR antagonist LY293558 reduces memory retrieval but has no effect on destabili-
zation or restabilization. The presynaptic mGlu2/3R agonist LY317206 reduces glutamate release, reducing memory retrieval via
AMPARs but leaving the balance of GluN2A and GluN2B activity intact (thus having no effect on destabilization or restabilization).
Milton et al. • GluN2B, GluN2A Mediate Different Memory Processes J. Neurosci., January 16, 2013 • 33(3):1109 –1115 • 1113
and Sara, 1997; Pedreira et al., 2002; Sadler et al., 2007; Brown
et al., 2008; Itzhak, 2008; Lee and Everitt, 2008; von der Goltz
et al., 2009) prevents the restabilization of memories. We hy-
pothesize (Fig. 6) that the differential effects of nonsubtype-
selective NMDAR antagonists on these mnemonic processes
depend upon the balance between signaling at GluN2B-
NMDARs and GluN2A-NMDARs, since only after the brief
destabilization process is there a requirement for the longer-
lasting restabilization process to be engaged. The differences
in duration of the two processes, subserved by different sub-
populations of NMDAR expressed within BLA neurons (Müller
et al., 2009), would suggest that the nonsubtype-selective NMDAR
antagonists tested in previous studies appear to be sufficient to pre-
vent GluN2A-dependent signaling, but fail significantly to affect
GluN2B-dependent signaling.
Thus, we hypothesize that nonselective NMDAR antagonists
exert their amnestic effects primarily through GluN2A-
containing NMDARs. Consistent with this view are the findings
that GluN2A-preferring NMDAR antagonists prevent the acqui-
sition of spatial memory (Hu et al., 2009) and conditioned fear
(Dalton et al., 2012), as do nonsubtype-selective NMDAR antag-
onists (Morris et al., 1986; Davis et al., 1992; Fanselow and Kim,
1994). Furthermore, the effects of nonselective NMDAR antago-
nists on other processes, such as cortical oscillations, are more
similar to the effects of GluN2A-preferring NMDAR antagonists
than GluN2B-selective NMDAR antagonists (Kocsis, 2012).
Thus, the glutamate transmission-dependent destabilization and
restabilization processes would be predicted to engage parallel,
independent molecular mechanisms mediated by the two sub-
types of NMDAR. This perspective can be integrated with already
known mechanisms underlying memory destabilization; for
example, GluN2B-containing NMDARs recruit the ubiquitin-
proteasome system via CaMKII (Bingol et al., 2010), thus allow-
ing the protein degradation that is required for the induction of
memory lability (Lee et al., 2008).
Surprisingly, we found a further dissociation in the mecha-
nisms underlying memory retrieval (dependent upon AMPARs)
and destabilization (dependent upon GluN2B-NMDARs). These
data refute our original hypothesis concerning AMPARs, al-
though they are consistent with previous findings that signaling
via AMPARs is necessary for memory expression and retrieval
(Day et al., 2003; Bast et al., 2005; Winters and Bussey, 2005). It is
perhaps surprising, from a theoretical perspective, that memory
retrieval and destabilization might be disrupted independently,
since reconsolidation theories maintain that memories must be
retrieved to become once again susceptible to disruption with
amnestic agents (Lewis, 1979; Nader, 2003). We therefore pro-
pose that the processes of memory retrieval and memory
destabilization are doubly dissociable, but that behavioral
procedures used to induce memory destabilization often in-
duce memory retrieval as well. This hypothesis clearly war-
rants further investigation.
As predicted, the LY317206-induced reduction in glutamate
release (Doherty et al., 1999) resulted in decreased activity at
AMPARs, GluN2B-NMDARs, and GluN2A-NMDARs and
hence no observable effect on memory retrieval, destabilization,
or restabilization. Although this is consistent with the mecha-
nisms shown in Figure 6, these data also indicate that such drugs
are unlikely to have utility in the treatment of maladaptive mem-
ories that characterize some neuropsychiatric disorders. There
has been interest in indirectly modulating signaling at NMDARs
by reducing glutamate release presynaptically since, as has been
noted previously (Milton and Everitt, 2010), systemic NMDAR
antagonists are unlikely to be used clinically because of their
problematic psychotomimetic side effects. However, our data do
support the view that selectively targeting GluN2A-NMDARs
may provide a useful therapeutic strategy; the psychotomimetic
effects of systemic NMDAR antagonism are likely mediated
through GluN2B-NMDARs (De Vry and Jentzsch, 2003), and so
it may be possible to develop GluN2A-NMDAR-selective thera-
pies that are appropriate for clinical use.
The results of these experiments reveal the complexity of the
glutamatergic mechanisms underlying CS–fear memory recon-
solidation within the BLA. In summary, GluN2A-containing and
GluN2B-containing NMDARs have dissociable roles in memory
restabilization and destabilization, respectively. While AMPARs
are required for memory retrieval, they do not appear necessary
for memory destabilization, suggesting that these two processes
are independently regulated. Furthermore, agonism at presynap-
tic mGlu2/3Rs has no overall effect on the strength of a CS–fear
memory. In addition to further elucidating the glutamatergic
mechanisms underlying the reconsolidation of fear memories,
these data also further support the possible utility of modulating
specific glutamate receptors in the clinical treatment of anxi-
ety disorders to disrupt persistent maladaptive and intrusive
memories.
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